Biotech Values

[oc631]

Another day another insider buy by an ACHN director




http://www.sec.gov/Archives/edgar/data/1070336/000118143113032925/xslF345X03/rrd382270.xml




Perhaps this is the penalty for not doing your job correctly?



The Sovaprevir/3102 combo will be years late entering a market with a non-durable patient population. The two leaders in GT1 clinical development (GILD and ABBV) just happen to be the powerhouses within the anti-viral space. They have the best salesforce and marketing teams and they will be entrenched when (or if) the ACHN combo gets approved. Remember BMY has a P.I./NS5A/Non-Nuke combo in late stage testing which will compete for market share with the incumbents.


So what does ACHN have besides false takeover rumors?


I'm not sure. I can tell you what they don't have. They don't have a third DAA class in the clinic. They don't have salesforce or marketing team. They don't have a partner to share the risk. They don't have an differentiated combo. They don't have IP or experience in nucleoside chemistry.

Wait I remember now. ACHN has a new CEO. Years after the BOD allowed this company to drive down a dead-end street. There's no floor underneath the share price if Sova/3102 fails safety.